

**Meeting Minutes, Open Session, Drug Utilization Review Board  
October 14, 2020**

**Drug Utilization Review Board**

\*Due to COVID-19, this meeting was held virtually.

**DUR Board Members:**

Moneeshindra Mittal, MD, Chair (Present)  
James Backes, PharmD, Interim Chair (Absent)  
Jennifer Clair, MD (Present)  
Katie Burenheide Foster, PharmD, MS, BCPS, FCCM (Present)  
Kristen Powell, PharmD (Present)  
LaTonyua Rice, PharmD, BCGP (Present)  
Arthur Snow, MD (Present)  
Serena Stutzman, APRN (Joined 10:34am) (Present)  
Roger Unruh DO (Present on Public line switched board line 10:57am) (Present)

**KDHE/DHCF/Contractor Staff:**

Annette Grant, RPh. (Present)  
Victor Nguyen, PharmD (Present)  
Carol Arace, Sr. Admin. (Present)

**DXC Technology Staff/KEPRO Staff**

Karen Kluczykowski, RPh (Present)  
Kathy Kaesewurm, RN, BSN (Present)  
Harry Vu, PharmD (Present)  
Christina Faulkner, PharmD, BCPS (Present)

**MCO Staff:**

Jan Mueller, RPh, UnitedHealthcare Community Plan (Present)  
Alan Carter, PharmD, Aetna Better Health of Kansas (Present)  
Angie Yoo, PharmD, Sunflower State Health Plan (Present)

**Public Attendees:**

Audrey Rattan, Bill Eicholzer, Chelsea Leroue, Cheryl Donahue, Chris Guenther, Dave Miley, Deborah Profant, Deron Grothe, Doug Wood, Erin Hohman, Gina Heinen, Ragal Govindarajan, Jean Ritter, Jeff Knappen, Jennifer Sabath, John Logan, Karen Floeder, Kari Walker, Kelli Amick, Kristi Kemp, Kim Walter, Kristin Jensen, Kurt Hendrickson, Laura Hill, Joni Still, Leslie Vanetti, Lucy Hernandez, Mackenzy Meinhardt, Mark Balk, Melissa Basal, Mindy Cameron, Patty Laster, Joe Payne, Rhonda Clark, Ricki Roberson, Sandy Chima, Scott Donald, Susie Moroney, Tara McKinley, Teresa Blair, Terry Ahlers, Todd Dickerson, Tracy Copeland, Jim baumann, Mandy Schnelten, Mary Shefchyk, Suzanne Tiller  
Sumaira Ahmed, Tina McCan

TOPIC	DISCUSSION	DECISION
I. Call to Order	Dr. Mittal called the meeting to order at 10:13 AM. Dr. Mittal re-called the meeting to order at 10:16 AM due to technical difficulties.	
Announcements and Introductions	The meeting operator informed every one of his role and the process for the meeting. Dr. Mittal asked the state for any announcements. The State introduced Dr. Chrissy Faulkner to the DUR Board.	
II. Old Business A. Review and Approval of September 10, 2020 Meeting Minutes	<b>Board Discussion:</b> Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Foster motioned to approve. Dr. Rice seconded the motion. The motion was approved unanimously. Dr. Mittal abstained due to being absent for the previous meeting.
III. New Business 1. Narcolepsy Agents	<b>Background:</b> PA criteria were initially approved in January 2020. Since then, Xywav™, a new formulation of oxybate, has been approved. Revised step-therapy criteria are being proposed to ensure appropriate and cost-effective use.  <b>Public Comment:</b> Deb Profant, Associate Director for Global Value from Jazz Pharmaceuticals: Spoke on Clinical efficacy and safety for Xywav.  <b>Board Discussion:</b> None	Dr. Powell motioned to approve. Dr. Foster seconded the motion. The motion was approved unanimously. Dr. Stutzman abstained due to joining late.
2. Monoamine Depletors	<b>Background:</b> These criteria were last revised in October of 2017. The PA criteria are being revised to clarify the suicide warnings and use of Austedo® (deutetrabenazine) in certain patients.  <b>Public Comment:</b> None.  <b>Board Discussion:</b> Dr. Foster asked if total chorea score needed to be included somewhere to help the MCO's. The State confirmed they should refer to original submission upon renewal.	Stutzman, APRN motioned to approve. Dr. Rice seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
<p><b>3. Duchenne Muscular Dystrophy Agents</b></p>	<p><b><u>Background:</u></b> This PA criteria consolidated several drugs into a single class PA and was initially approved in July 2020. Since then, Viltepso™ (viltolarsen) has been approved. Revised criteria are being proposed to ensure appropriate use.</p> <p><b><u>Public Comment:</u></b> None</p> <p><b><u>Board Discussion:</u></b> None</p>	<p>Dr. Clair motioned for approval. Dr. Foster seconded the motion. The motion was approved unanimously.</p>
<p><b>4. Acute Migraine Agents</b></p>	<p><b><u>Background:</u></b> These criteria were initially approved in July 2020. They are being presented again to review recommendations made regarding provider type and scoring assessments. The State revisited discussions on the mTOQ, explaining that there was a shorter version that was more appropriate for clinical practice. The provider type requirement of neurologist was replaced with criteria regarding red-flag symptoms. The renewal criteria were also revised.</p> <p><b><u>Public Comment:</u></b> None</p> <p><b><u>Board Discussion:</u></b> Dr. Powell requested clarification that red flags were meant to signal that something else is occurring. The State confirmed that these were intended to assist primary care physicians evaluate the patient and determine if referral is needed.</p>	<p>Dr. Snow motioned to approve. Dr. Foster seconded the motion. The motion was approved unanimously.</p>

<p><b>5. Chemotherapy Agents</b></p>	<p><b><u>Background:</u></b>  These criteria were last reviewed in October 2018. Additional drugs are being proposed for inclusion. Criteria revisions are also being proposed to ensure appropriate use based upon FDA-approved labeling and clinical guidelines.  MCOs would be allowed to use support teams specialized in chemotherapies to aid in the approval process. Potentially, approvals would go beyond the currently proposed criteria with the overall goal of better patient treatment.</p> <p><b><u>Public Comment:</u></b></p> <ul style="list-style-type: none"> <li>• Susie Moroney, Hematology Oncology Pharmacist for Novartis Oncology: Thanked the State for simplifying the criteria and requested to add Tavegyl (nabilon) to this PA.</li> <li>• Laura Hill, Medical Outcomes Science Liaison for AbbVie: Thanked the State for simplifying the criteria and inquired about new products being added to the list.</li> <li>• Mark Balk, Pharm D for BeiGene: Spoke on the efficacy of Brukinsa (Zanubrutinib) and requested to have Brukinsa added to policy.</li> </ul> <p><b><u>Board Discussion:</u></b>  Dr. Foster asked how requests are handled if the drug is also used to treat rheumatoid arthritis or other non-oncology related indications. The State responded that they would be covered in a separate class PA, such as Rituxan in the Rheumatoid Arthritis PA.  Dr. Powell requested a clarification on how new drugs would be added. The State responded that it would be brought back as an agenda item through the DUR meetings.  Dr. Powell asked whether simplifying criteria would be helpful to the MCOs. Sunflower confirmed that it would be helpful.</p>	<p>Dr. Powell motioned to approve as amended.  Stutzman, APRN seconded the motion.  The motion was approved unanimously.</p>
<p><b>6. Botulinum Toxins</b></p>	<p><b><u>Background:</u></b>  These criteria were last reviewed in July 2014. Since then, labeling changes to Botox®, Dysport®, and Xeomin® have occurred. Criteria revisions are being proposed to ensure appropriate use based upon FDA approved labeling.</p> <p><b><u>Public Comment:</u></b> None</p>	<p>Dr. Snow motioned to approve.  Stutzman, APRN seconded the motion.  The motion was approved unanimously</p>

	<b>Board Discussion:</b> None	
<b>B. New Prior Authorization (PA) Criteria</b>  <b>1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents</b>	<b>Background:</b> Multiple medications are now approved for the treatment of NMOSD, including Soliris®, Uplizna™, and Enspryng™. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.  <b>Public Comment:</b> None  <b>Board Discussion:</b> None	Dr. Foster motioned to approve. Dr. Unruh seconded the motion. The motion was approved unanimously.
<b>C. Miscellaneous Items</b> <b>1. Fee-for-Service Annual Program Assessment</b>	<b>Background:</b> The annual program assessment for the Medicaid fee-for-service population will be presented to show drug trends over the past state fiscal year.  <b>Board Discussion:</b> None	Dr. Mittal asked that Power Point Presentations to be emailed to Board.
<b>2. Managed Care Annual Program Assessment</b>	<b>Background:</b> Aetna Better Health of Kansas, Sunflower State Health Plan, and UnitedHealthcare Community Plan will present reports detailing utilization trends and provider education efforts for 2019. <ul style="list-style-type: none"> <li>• Aetna Individual Report – Alan Carter, PharmD</li> <li>• Sunflower Individual Report – Angie Yoo, PharmD</li> <li>• UnitedHealthcare Individual Report – Janette Mueller, RPh</li> </ul>	
<b>IV. Open Public Comment</b>	<ul style="list-style-type: none"> <li>• Sumaira Ahmed, NMOSD patient and patient advocate (NMOSD): Advocated for open and appropriate access to therapies.</li> <li>• Dr. Ragal Govindarajan, board certified neurologist (NMOSD): Requested open access for treatment for NMOSD with no step therapy or preferred agent. The State confirmed that there was no step therapy nor preferred agent. The key intent of the criteria was to ensure that the agents were being used for the appropriate patients (AQP4-positive patients).</li> </ul>	

	<ul style="list-style-type: none"> <li>• Erin Hohman, Janssen Pharmaceuticals (Chemotherapy Agents): Requested for Balversa and Darzalex to be added to agent list.</li> <li>• Chris Guenther, healthcare director, Genentech (Chemotherapy Agents): Requested to add additional drugs at the next DUR Board meeting and thanked the Board for refining overall process for oncology agents.</li> <li>• Chelsea Leroue, Medical Affairs, Biohaven Pharmaceuticals (Acute Migraines): Suggested that the -gepant drug class was not associated with medication overuse headache. Chelsea expressed concern about patient access to therapy. The State noted that the deadline for public comment on specific agenda items is one week prior to the meeting and that no further changes will be considered.</li> </ul>	<p>Dr. Powell motioned to reopen Chemotherapy agents. Dr. Clair seconded The motion was approved unanimously.</p> <p>Dr. Clair motioned to approve as amended. Dr. Snow seconded the motion. Motion was approved unanimously.</p>
<b>V. Adjourn</b>	The meeting adjourned at 12:42pm	Stutzman, APRN motioned to adjourn. Dr. Snow seconded the motion. Motion to adjourn carried unanimously.

**The next DUR Board meeting is scheduled for January 20, 2021.**

All approved PA criteria are posted to the KDHE website- [http://www.kdheks.gov/hcf/pharmacy/pa\\_criteria.htm](http://www.kdheks.gov/hcf/pharmacy/pa_criteria.htm)